Peptide Library

Human study PLS-00159

Thymosin beta4 levels after successful primary percutaneous coronary intervention for acute myocardial infarction.

Case-control study · 48 participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Thymosin beta4 levels after successful primary percutaneous coronary intervention for acute myocardial infarction.primary · Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir · 2011-12-01 · PMID 22257803 · DOI

Design and participants

Design
Case-control study
Population
24 consecutive patients with ST-elevation acute myocardial infarction who underwent successful primary PCI, and 24 age- and sex-matched controls with angiographically normal coronary arteries.
Conditions
ST-elevation acute myocardial infarction
Setting
Patients undergoing coronary angiography or primary PCI; the centre is not stated.
Planned enrollment (registry)
Not reported
Enrolled
48
Randomized
Not reported
Completed follow-up
Not reported
Funding
Not stated
Authors’ conflicts
Not stated

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable; no compound was administered and no adverse events were reported.

    The authors concluded (paraphrased): Because serum Tβ4 rose significantly after successful primary PCI in STEMI patients, the authors suggest Tβ4 may become a new marker for assessing reperfusion success.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Tβ4 was not administered. Only endogenous levels were measured, so the study gives no evidence on treatment effects.
    • small or imprecise: Only 24 patients and 24 controls were enrolled.
    • abstract only: Only the abstract is available, and its results section is truncated.
    • inappropriate endpoint: The outcome is a serum biomarker level, not a clinical outcome.
    • inappropriate population: No Tβ4 was administered. The study measured endogenous levels in MI patients, so it cannot inform effects or safety of Tβ4 treatment.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 22257803, abstract (Study design, sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 22257803, abstract (Conclusion, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 22257803, abstract (Study design, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 22257803, abstract (Results, sentence 1 (truncated)) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 22257803, abstract (Study design, sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 22257803, abstract (Study design, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 22257803, abstract (Study design, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • results: PMID 22257803, abstract (Conclusion, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).